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AbstrAct
In this study, we examined the role of the miRNA miR-770-5p in cisplatin 
chemotherapy resistance in ovarian cancer (OVC) patients. miR-770-5p expression 
was reduced in platinum-resistant patients. Using a 6.128-fold in expression as the 
cutoff value, miR-770-5p expression served as a prognostic biomarker and predicted 
the response to cisplatin treatment and survival among OVC patients. Overexpression 
of miR-770-5p in vitro reduced survival in chemoresistant cell lines after cisplatin 
treatment. ERCC2, a target gene of miR-770-5p that participates in the NER system, 
was negatively regulated by miR-770-5p. siRNA-mediated silencing of ERCC2 reversed 
the inhibition of apoptosis resulting from miR-770-5p downreglation in A2780S cells. 
A comet assay confirmed that this restoration of cisplatin chemosensitivity was due 
to the inhibition of DNA repair. These findings suggest that endogenous miR-770-5p 
may function as an anti-oncogene and promote chemosensitivity in OVC, at least in 
part by downregulating ERCC2. miR-770-5p may therefore be a useful biomarker for 
predicting chemosensitivity to cisplatin in OVC patients and improve the selection of 
effective, more personalized, treatment strategies.
IntroductIon
Ovarian cancer (OVC) is the leading cause 
of death due to gynecologic malignancies among 
women in developed countries. Epithelial ovarian 
cancer (EOC), which has a poor prognosis due to late 
diagnosis and high incidences of chemoresistance, 
accounts for approximately 90% of OVCs [1, 2]. The 
standard treatment protocol for the initial management 
of OVC is cytoreductive surgery, followed by primary 
chemotherapy with a platinum-based regimen [3, 4]. 
However, drug resistance is a major impediment to 
the successful treatment of OVC with chemotherapy. 
Chemoresistance often results in significant toxicities, 
such as declining bone marrow reserves, which delay 
the initiation of therapy with active chemo-agents and 
reduce quality of life [3]. Early prediction of OVC 
patient response to platinum-based chemotherapy 
and identification of the most effective agent based 
on primary tumor gene expression data may assist 
in optimizing the selection of personalized treatment 
regimens. 
Platinum (cisplatin or carboplatin) is the first-
line chemotherapeutic drug for OVC patients and a 
mainstay of standard treatment for advanced EOC 
[5, 6]. The major effect of cisplatin treatment involves 
DNA binding, the production of intrastrand (or 
interstrand) structural crosslinks, and the formation 
of DNA adducts [7–10]. Nucleotide damage repair 
and DNA repair capacity (DRC) play critical roles 
in the removal of cisplatin-induced lesions, leading 
to altered cell growth, differentiation, apoptosis, 
and carcinogenesis, and thus affecting response to 
chemotherapy and chemoresistance [7, 11].
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Recent evidence indicates that microRNAs 
(miRNAs) play important roles in various pathways 
related to anticancer drug resistance, e.g., influencing 
the response to the conventional chemo-agents cisplatin 
and microtubule-targeting drugs [12–15]. However, 
whether and how miRNAs predict chemosensitivity 
and mediate drug resistance in OVC requires further 
investigation. In this study, we identified miRNAs that 
are differentially expressed in EOC patients who show 
complete responses (CR) or incomplete responses (IR) 
to primary platinum-based chemotherapy. We coupled 
this analysis with bio-functional experiments to 
determine how oncogenic-miRNA signaling pathways 
impact platinum-resistance. Our findings suggest that 
integrating miRNA expression profiles that predict 
platinum response, and understanding the mechanisms 
by which miRNAs affect chemoresistance, might 
improve the selection of personalized treatment plans 
for individual EOC patients.
rEsuLts 
Patient characteristics
We evaluated 86 serous EOC samples resected at the 
time of primary surgery from patients who subsequently 
received platinum-based primary therapy. All samples 
were collected at the Obstetrics and Gynecology Hospital, 
Dalian, China between July 2004 and November 2010. 
Fifty-two EOC patients showed a CR, and 34 showed an 
IR, to primary platinum-based therapy following surgery. 
Patient clinical characteristics are listed in Table 1.
mir-770-5p is downregulated in chemotherapy-
resistant Eoc patients
To identify miRNA expression signatures 
associated with resistance to chemotherapy in EOC 
patients, patient specimens were initially analyzed by 
miRNA microarray, the results of which were validated 
with qRT-PCR and qualitative in situ hybridization (ISH). 
Of the 768 miRNAs analyzed in the microarray, levels 
of 39 differed at least 2-fold (p < 0.05) between CR 
and IR patients (n = 7 /group). Thirty-four (87.2%) of 
these 39 miRNAs were upregulated in the CR samples, 
and 5 (12.8%) were upregulated in the IR specimens 
(Figure 1A). Importantly, 2 of the 3 miRNAs with the 
most statistically significant differences (p < 0.0001) were 
upregulated in CR patients; the other was upregulated in 
IR patients. One of these three miRNAs, miR-770-5p, 
was upregulated 2.9-fold in the CR group versus the 
IR group (p = 1.66E–06, adjusted p-value = 8.78E–04) 
(Figure 1A and Supplementary Table S1). To confirm this 
finding, we examined miR-770-5p expression using qRT-
PCR and ISH. As shown in Figure 1B–1C, miR-770-5p 
expression was lower in IR patients than in CR patients. 
Target prediction was performed for miR-770-5p 
using three computational approaches: Ingenuity 
Systems (Redwood City CA, USA), MicroCosm Targets 
version 5, and miRBase. As cisplatin primarily functions 
through binding or/and crosslinking to DNA, targets 
were predicted by focusing on the “DNA Replication, 
Recombination, and Repair” area. The top nine candidate 
targets related to DNA replication and repair functions are 
listed in Figure 1D.
Prediction of chemotherapy response and 
survival rate in Eoc patients based on mir-770-
5p expression
We then examined the relationship between miR-
770-5p expression and primary chemo-responsiveness 
in patients in a retrospective study. A 53-sample training 
cohort was used to identify the miR-770-5p expression 
level that predicted clinical outcome. A 6.128-fold 
in expression served as the cutoff value for accurate 
prediction of response probability as determined by 
receiver operating characteristic (ROC) curve analysis 
(Figure 2A). Patient response to platinum-based therapy 
was accurately predicted in 43 of 53 patients for an overall 
accuracy of 81.1% (sensitivity, 80% and specificity, 
83%) (Figure 2B). A Mann-Whitney U test for statistical 
significance (p < 0.001) confirmed that this predictor 
distinguished IR patients from CR patients. The mean 
AUC value (area under ROC curve) was 0.849.
To confirm the predictive value of miR-770-5p 
expression for primary chemosensitivity, we used miR-
770-5p expression to predict primary chemoresistance 
in a separate group of patients before treatment with 
a platinum-based regimen. miR-770-5p expression 
accurately predicted primary chemotherapy response 
in this validation cohort (76% accuracy; Figure 2C). 
Kaplan-Meier survival analysis revealed that low miR-
770-5p expression was associated with shorter overall 
survival in OVC patients compared to the high miR-770-
5p expression group (Figure 2D–2F).
Taken together, these results indicate that miR-
770-5p expression level may serve as a novel predictor 
and prognostic biomarker of OVC patient response to 
platinum-based chemotherapy and survival.
overexpression of mir-770-5p inhibits survival 
in cisplatin-chemoresistant cell lines
Based on the above results (Figure 1A–1C), we 
further confirmed the relationship between miR-770-5p 
expression and chemosensitivity in the human ovarian 
cancer cell lines OV2008 and A2780S and their cisplatin-
resistant variants C13 and A2780CP, respectively. As 
indicated in Supplementary Figure S1, miR-770-5p 
expression was upregulated in OV2008 and A2780S cell 
lines compared to the cisplatin-resistant variants. These 
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results agree with those from the clinical OVC patient 
specimens. 
We then investigated the effects of miR-770-5p 
overexpression on sensitivity to cisplatin chemotherapy in 
the resistant cell lines after treatment with various cisplatin 
concentrations or following various durations of miR-770-
5p transfection in vitro. Transfection with pre-miR-770-5p 
reduced C13 and A2780CP cell viability relative to the 
mock and negative control groups (Figure 3A and 3B). 
C13 and A2780CP cell survival was also markedly 
decreased after pre-miR-770-5p transfection and 24 hours 
of cisplatin treatment (Figure 3D).
Ercc2 is a potential target of mir-770-5p
Nucleotide excision repair (NER) has been reported to 
play a role in regulating both chemoresistance and apoptosis 
[16]. ERCC2, one of the candidate target genes involved 
in NER, contains a putative region (nucleotides 279–301 
in the human sequence 3′-UTR, NM_000400.2) that 
matches the seed sequence of hsa-miR-770-5p (Figure 4A). 
To determine whether ERCC2 is a target of miR-770-5p, 
quantitative and qualitative analysis at both the miRNA and 
mRNA levels were performed in vivo and in vitro. 
First, miR-770-5p and ERCC2 expression were 
analyzed in CR and IR patients using qRT-PCR; miR-
770-5p expression was negatively correlated with 
ERCC2 expression in both groups (Figure 4B). It is well-
established that miRNAs suppress target gene expression 
primarily by inhibiting translation and/or induction of 
mRNA cleavage, and reciprocal expression patterns 
between an miRNA and the mRNA of its target gene can 
be detected in the same patient specimen. To confirm 
the miRNA-target relationship between miR-770-5p 
and ERCC2, miRNA and mRNA ISH was performed. 
Figure 4C shows the qualitative validation of miR-770-5p 
and its predicted target, ERCC2, in FFPE serial sections 
from same EOC patient. In the CR group, miR-770-
5p was strongly expressed in the cancer epithelium, but 
ERCC2 expression was weak or undetectable in the same 
tumor tissues from the same patient. The same relationship 
between miR-770-5p and ERCC2 was also observed in 
IR patients. Quantitative analysis using Image-Pro 6.0 
software confirmed an inverse relationship between miR-
770-5p and ERCC2 mRNA expression in the CR and IR 
groups (Figure 4D).
To determine whether ERCC2 is also modulated by 
miR-770-5p in vitro, the cisplatin-sensitive parental cell 
lines (OV2008, A2780S) and their resistant variants (C13 
and A2780CP) were transfected with anti-miR-770-5p or 
pre-miR-770-5p, respectively. Western blotting and semi-
quantitative RT-PCR analyses revealed that miR-770-5p 
negatively regulated ERCC2 expression at both the mRNA 
and protein levels (Figure 4E). 
Ercc2 and mir-770-5p modulate sensitivity 
of ovarian cancer cells to cisplatin-induced 
apoptosis 
To determine how ERCC2 modulates 
chemosensitivity, we used siRNA to silence ERCC2 
expression (siERCC2) in A2780S cells transfected with 
an miR-770-5p inhibitor. We then measured cisplatin-
induced apoptosis in these cells with flow cytometry and 
table 1: clinicopathologic characteristics of ovarian cancer patients
characteristic
clinical complete
responders
(n = 52)
clinical Incomplete
responders
(n = 34)
Meanage,years 50.8 48
Stage, No. of patients
 I 3 2
 II 8 7
 III 41 21
 IV 0 4
Grade, No. of patients
 1  3 2
 2 28 14
 3 21 18
Mean serum CA-125, m/mL
 Before platinum 993.2 1884.4
 After platinum 12.1 205.6
Mean survival time, months 46 30
Mortality rate (%) 48.3 70
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TUNEL assays. A2780S cells became more resistant to 
cisplatin after transient transfection-mediated miR-770-5p 
silencing (Figure 5A–5C). Furthermore, silencing ERCC2 
expression in A2780S cells treated with the miR-770-5p 
inhibitor restored chemosensitivity to cisplatin as indicated 
by both flow cytometry and TUNEL assays (Figure 5). 
upregulation of mir-770-5p and downregulation 
of Ercc2 inhibits the repair of cisplatin-
induced dnA-damage in vitro
Cisplatin and other platinum-based cancer drugs 
destroy tumor cells by binding to DNA strands, interfering 
with DNA replication, and forming cisplatin-DNA 
adducts; chemosensitivity results from the inability to 
repair this DNA damage. Because the effects of miR-770-
5p on DNA repair might explain its ability to modulate 
cisplatin-resistance in ovarian cancer, we examined 
the role of ERCC2 in this repair process. In order to 
quantify the DNA damage/repair process, we measured 
the percentage of DNA in comet tails; tail length (in μm), 
tail moment (TM), and tail olives moment (TOM) were 
measured in each gel (Figure 6A–6B). DNA damage was 
measured manually and evaluated with CASP version 
1.2.3 beta2 (Figure 6C–6D). As expected, DNA damage 
repair-deficient A2780S cells had smaller tails than 
Figure 1: mir-770-5p expression is reduced in patients with chemotherapy-resistant Eoc, and target predictions. (A) 
Hierarchical clustering of miRNA microarray analysis in complete response (CR) and incomplete response (IR) ovarian cancer patients. 
Two miRNAs (miR-770-5p and hsa-miR-136*, red circle) were more highly expressed (p < 0.0001) in the CR group, and one (hsa-miR-9, 
green circle) was more highly expressed in the IR group. (b) Differential miR-770-5p expression in CR and IR patients. (c) Analysis of 
miR-770-5p expression in CR and IR sample sets using in situ hybridization. miR-770-5p expression was higher in CR than in IR samples 
(p < 0.001). (d) miRNA target prediction and top bio-functional analysis using Ingenuity Systems software. The predicted top nine targets 
were related to DNA replication, recombination, and repair.
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Figure 2: mir-770-5p levels predict response to platinum-based chemotherapy and survival in oVc patients. (A) 
Leave-one-out cross prediction of cisplatin responders (blue: CR, yellow: IR), n = 53. a 6.128 in expression was the cutoff value having the 
highest Youden’s index; accuracy, sensitivity, and specificity were 81.1%, 80%, and 83% respectively. (b) Receiver operating characteristic 
(ROC) curve of the cisplatin responders. A Mann-Whitney U test demonstrated that miR-770-5p expression distinguished IR patients from 
CR patients (p < 0.001). Mean AUC is 0.849 (0.79–0.91). (c) Confirmation that the 6.128 cutoff predicted cisplatin response prediction as 
indicated by ROC curve analysis. (d) In 47 randomly selected OVC patients, overall survival was higher in those with high miR-770-5p 
expression (CR = 28, IR = 19; p < 0.05). (E–F). Overall survival of CR and IR patients divided into high and low miR-770-5p subgroups. 
Kaplan-Meier survival analysis also indicated that low miR-770-5p expression was associated with shorter overall survival compared to 
the high expression group (n = 25 for CR and n = 15 for IR, p < 0.001 for CR group, p < 0.05 for IR group). AUC: area under the curve.
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Figure 3: overexpression of mir-770-5p inhibits survival of chemo-resistant cell lines after cisplatin treatment. (A) 
Transfection with pre-miR-770-5p inhibited survival in C13 and A2780CP cells treated with various concentrations of cisplatin compared 
to mock and negative control groups (n = 10 for all groups). (b) Viability decreased in C13 and A2780CP cells after different lengths (0 to 
96 h) of miR-770-5p transfection compared to mock and negative control groups (c) Real-time RT-PCR confirmed the success of pre-miR-
770-5p transfection. (d) Pre-miR-770-5p, negative control, and mock transfected cell lines (C13 and A2780CP) were cultured in media 
containing cisplatin. Cell numbers were counted after 48 hours of treatment. †, statistically significant difference in miR-770-5p expression 
compared to either negative control or mock-transfected cells (all p < 0.01).  
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A2780CP cells. After transfection with the miR-770-5p 
inhibitor, A2780S DNA repair abilities increased, 
suggesting that these cells became more resistant to 
cisplatin. However,  siRNA-mediated ERCC2 silencing 
reversed this increase. In addition, silencing ERCC2 
inhibited DNA damage repair similarly to miR-770-5p 
upregulation in A2780CP cells (Figure 6). A representative 
image of the modified COMET assay used for data 
analysis is shown in Figure 5B. These results indicate that 
the effect of miR-770-5p on cisplatin-sensitivity was at 
least partly mediated by ERCC2.
dIscussIon
Platinum-based chemotherapy is the standard first-
line treatment for advanced-stage EOC, and cisplatin is the 
drug used most often after primary surgery [3]. However, 
about 30–40% of patients who receive platinum-based 
chemotherapy experience disease progression or rapidly 
develop resistance to this non-targeted therapy [3, 17]. 
Therefore, early identification of platinum sensitivity 
would benefit platinum-resistant EOC patients, for whom 
other first-line therapies could be used [3, 17,18–22]. 
Using miRNA microarrays, qRT-PCR, and ISH, 
we demonstrated that some miRNAs are differentially 
expressed in EOC patients who show CRs or IRs to 
primary chemotherapy. Preliminary experiments and 
comprehensive computational analysis identified miR-
770-5p as a particularly relevant miRNA. miR-770-5p was 
downregulated in chemoresistant EOC patients, indicating 
that miRNAs are involved in the response to platinum-
based regimens. To determine the impact of miR-770-
5p on chemoresistance, we performed retrospective and 
prospective assessments of miR-770-5p as a predictor 
Figure 4: mir-770-5p inhibits Ercc2 in vivo and in vitro. (A) Sequence alignment of human miR-770-5p with the 3′-UTR of 
ERCC2. (b) Differences in miR-770-5p (left panel) and ERCC2 (right panel) expression between the CR and IR groups. (c) Qualitative 
and quantitative examination of miR-770-5p and ERCC2 expression by ISH in FFPE sections from EOC patients. hsa-miR-770-5p was 
highly expressed in the tumor epithelium (green arrows in ii) of CR patients (i-iv), and ERCC2 expression was absent in the same tumor 
area (in iv). In contrast, IR tumors (v-viii) expressed low levels of hsa-miR-770-5p, but higher levels of ERCC2 (green arrows in viii). The 
areas in white boxes are shown enlarged on the right. (d) Quantitative analysis of miR-770-5p (miRNA) and ERCC2 (mRNA) expression 
in tumors conducted with Image-Pro 6.0 (positive areas: white color; IOD: integrated optical density) (E) Overexpression of miR-770-5p 
downregulates ERCC2 protein and mRNA levels in C13/A2780CP cells, and anti-miR-770-5p-treatment reversed this effect in OV2008/
A2780S cells (all p < 0.05).
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Figure 5: Effects of Ercc2 on mir-770-5p-modulated chemoresistance in ovarian cancer cells. (A) Flow cytometric 
detection of apoptosis via Annexin V-FITC/PI staining in cisplatin-sensitive A2780S cells after treatment with cisplatin (20 μM) for 
48 h after transfection with miR-770-5p inhibitor, negative control, or miR-770-5p inhibitor + siERCC2. (b) After transfection with 
miR770-5p inhibitor, A2780S cells were treated with cisplatin (40 μM) for 24 h. TUNEL staining indicated that apoptosis decreased after 
cisplatin treatment in A2780S cells transfected with miR-770-5p inhibitor; siRNA-mediated ERCC2 silencing reversed this effect. Original 
magnification: 400×. (c) Analysis of flow cytometry results (left, n = 10/group) and TUNEL staining (right, n = 6/group). Statistical 
analyses of percent values and time to 50% apoptosis were conducted using Pearson’s χ2 test and ANOVA, respectively. (d) RT-PCR and 
western blot analysis confirmed that siRNA inhibited the expression of ERCC2 mRNA and protein in A2780 cell lines. †p < 0.001. 
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Figure 6: cAsP comet analysis of alkaline comet assay images. (A) Representative image of the modified COMET assay used 
to evaluate DNA damage after treatment with cisplatin. The blue arrow indicates a comet with a long tail, and yellow arrow a comet with 
a short tail. The scale bar is 100 μm. (b) Alkaline comet assay images for each group after cisplatin treatment are shown on the left, and 
CASP comet output and analysis are shown on the right. Red lines (indicated by red arrows) represent the head of comet, and green lines 
(indicated by green arrows) represent the tail of comet. (c) Amounts of DNA damage with and without cisplatin treatment in each group. 
†p < 0.001. 1: A2780S NC, 2: A2780S miR-770-5p inhibitor, 3: A2780S miR-770-5p inhibitor + siERCC2, 4: A2780CP NC, 5: A2780CP 
miR-770-5p mimics, 6: A2780CP siERCC2. (d) Spontaneous and cisplatin-induced means ± S.D. for three additional replicates of the 
Comet assay after cisplatin treatment. ¶p < 0.001 compared to negative controls of the same cell type; †p < 0.001 compared to the scrambled 
miR-770-5p or mimics group of the same cell type.
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of primary chemosensitivity before and after patients 
received a platinum-based regimen. Unexpectedly, high 
miR-770-5p expression predicted chemoresistance with an 
accuracy of up to 81.1% in the retrospective and 76% in 
prospective assessments, with a 6.128-fold in expression 
serving as the cutoff value. This finding demonstrates that 
miR-770-5p expression immediately after primary EOC 
diagnosis can be used as a biomarker to assist in selecting 
the appropriate chemotherapy regimen before treatment 
begins, helping to avoid unnecessary toxicities and 
enhance quality of life. To confirm the association between 
miR-770-5p and chemo-resistance in vitro, we transiently 
transfected OVC cell lines with an miR-770-5p expression 
vector. Ectopic miR-770-5p expression increased survival 
and reduced apoptosis in ovarian cancer cells, suggesting 
that miR-770-5p also modulates therapeutic response. 
To understand the mechanism by which miR-770-5p 
regulates chemoresistance in OVC, we identified possible 
target genes using computational approaches. One of the 
candidate targets was ERCC2, a gene in the NER system 
that is involved in DNA replication, recombination, 
and repair [7, 23–25]. Cisplatin activity is mediated 
through the formation of cisplatin-DNA adducts [26]. 
The NER system removes these adducts, which can lead 
to chemoresistance, and DRC thus plays a critical role 
in the response to chemotherapy and chemo-resistance 
[7, 11]; reduced DRC may increase the response to 
chemotherapies that damage cancer cell DNA. Here, we 
detected an inverse correlation between miR-770-5p and 
ERCC2 expression both in tumor specimens from OVC 
patients who received platinum-based chemotherapy and 
in vitro.  
To determine how ERCC2 and miR-770-5p act 
together to modulate cisplatin-resistance, we used siRNAs 
to silence ERCC2 expression (siERCC2) in A2780S 
cells transfected with an miR-770-5p inhibitor. siRNA-
mediated silencing of ERCC2 reversed the inhibition of 
apoptosis that resulted from miR-770-5p downregulation 
in A2780S cells. To investigate the mechanism underlying 
this effect, the comet assay, a sensitive and reliable method 
for studying DNA damage induced by platinum and 
other chemical agents, was used to assess DNA damage 
and DRC [27]. The results confirmed that the inhibition 
of apoptosis was due to increased DRC. Together, these 
findings suggest that miR-770-5p might directly target 
ERCC2, the downregulation of which increases cisplatin 
chemosensitivity in OVC. Thus, the anti-oncogenic and 
cisplatin chemosensitivity-enhancing effects of miR-770-
5p in OVC might depend on its ability to downregulate 
ERCC2 expression (Figure 7). 
Figure 7: schematic model depicting mediation of response to cisplatin-based primary chemotherapy by mir-770-5p 
and Ercc2 oVc patients. (A) The general mechanism of ERCC2-dependent DNA damage repair after cisplatin treatment in OVC 
patients. After the DNA intra-strand is unwound and damaged by cisplatin, ERCC2 recognizes and repairs the DNA adducts. In OVC 
patients with IR to cisplatin, miR-770-5p is downregulated and does not suppress ERCC2 expression; ERCC2 is thus overexpressed in 
OVC cells and activates excision repair of DNA damaged by cisplatin, ultimately accelerating tumor cell growth (b) Conversely, in OVC 
patients with CR to cisplatin, miR-770-5p is upregulated and strongly suppresses ERCC2 expression in tumor cells; this reduces ERCC2-
induced DNA damage repair, allowing cisplatin to damage DNA and ultimately activating tumor cell apoptosis (c) ERCC2 = excision 
repair cross-complementing rodent repair deficiency, group 2; IR = incomplete response; CR = complete response. 
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Pharmacokinetic analyses of miRNAs are an 
innovative method for predicting treatment response and 
chemoresistance [12, 28]. In this study, we report that 
miR-770-5p enhances chemosensitivity at least in part 
by targeting ERCC2. Therefore, the miR-770-5p-ERCC2 
interaction might be a useful biomarker for predicting 
chemosensitivity to cisplatin in OVC patients. Future 
examinations of miRNA expression profiles coupled with 
the expression of valid targets might improve predictions 
of sensitivity to primary chemotherapy and assist in the 
development of effective individualized cancer treatments. 
MAtErIALs And MEtHods
Patient samples and cell lines
We evaluated a total of 86 serous EOC samples 
resected at the time of primary surgery from patients 
who went on to receive platinum-based chemotherapy. 
The clinicopathologic characteristics of these patients 
are listed in Table 1. All tissue samples were collected at 
the Obstetrics and Gynecology Hospital, Dalian, China 
between July 2004 and November 2010. Two independent 
pathologists with no knowledge of the patients’ clinical 
data reviewed the pathological specimens before they 
were formalin fixed and paraffin embedded (FFPE). 
Cases were classified according to the International 
Federation of Gynecology and Obstetrics (FIGO) staging 
system. Therapeutic response was evaluated as previously 
reported [29]. Medical records were examined by a 
single gynecologic oncologist and scored using standard 
criteria for patients with measurable disease based on 
WHO guidelines [29, 30]. A complete response (CR) was 
classified as a complete disappearance of all measurable 
and assessable disease or, in the absence of measurable 
lesions, by CA-125 levels < 30 U/mL measured by RIA 
or ELISA six months after treatment with platinum-based 
drugs. CA-125 response criteria were based on established 
guidelines [29, 31, 32]. Patients who exhibited only a 
partial response, had no response, or progressed during 
primary therapy were classified as having an incomplete 
response (IR). Fifty-two OVC patients showed a CR and 
34 showed an IR after primary platinum-based therapy 
following the surgery. FFPE blocks were obtained after 
surgery. 
In vitro experiments were performed with two 
different pairs of human OVC cell lines; each pair 
included one cisplatin-sensitive parental cell line (A2780S 
and OV2008) and its cisplatin-resistant variant (A2780CP 
and C13, respectively) [33, 34]. 
cell culture, transfection and treatment
Ovarian cancer cells were cultured in RPMI-1640 
medium (Invitrogen, Burlington, ON) supplemented 
with 10% fetal bovine serum and maintained at 37°C 
with 5% CO2 as reported previously [33, 34]. All tissue 
culture reagents were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). The miR-770-5p mimics and 
inhibitors were designed and chemically synthesized by 
Ambion (Cat#38422-01; Life Technologies Corporation, 
Denmark). 
Lipofectamine 2000 (Invitrogen) was incubated 
with pre-miR-770-5p (miRNA mimic), anti-miR-770-
5p (inhibitor), or scrambled negative controls (Ambion, 
mock) at a concentration of 90 nM and incubated in 
serum-free 1640 for 20 min before being added to cancer 
cells. Cells were incubated at 37°C for 4 h and then 
transferred to 10% FBS. Protein and RNA were harvested 
48 h after transfection. For cisplatin treatment, cells were 
maintained in medium with the desired doses of cisplatin 
(Cat# P4394; Sigma, USA).
mirnA microarray and data analysis
A microarray platform optimized for the analysis 
of a panel of 768 human miRNAs was used to analyze 
and compare miRNA expression patterns between EOC 
patients who showed a CR (n = 7) or an IR (n = 7) to 
platinum-based chemotherapy. Total RNA enriched for 
miRNAs was extracted from FFPE tissues using the 
Ambion mirVana microRNA isolation kit (Cat#AM1975; 
Ambion, USA). The quality of total RNA was assessed 
using an Agilent Bioanalyzer (Agilent Technologies, Santa 
Clara CA). Individual real-time quantitative polymerase 
chain reaction assays were performed in a TaqMan 
low-density array (TLDA; Applied Biosystems) by the 
Shannon McCormack Advanced Molecular Diagnostics 
Laboratory Research Services, Dana Farber Cancer 
Institute, Harvard Clinic and Translational Science Center. 
The normalized microarray data were analyzed using 
Statminer version 3.0 (Integromics™) software.
mirnA target prediction and pathway analysis
miRNAs target prediction was conducted using 
three computational approaches: Ingenuity Systems 
(Redwood City CA, USA), MicroCosm Targets version 
5 (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/
targets/v5/), and miRBase (http://www.mirbase.org/). 
The target prediction algorithm used here is estimated 
to have a 20–30% false-positive rate. This level of 
false discovery is unlikely to affect the overall network 
findings, despite the large number of top predicted gene 
targets. Functional analysis of these predicted targets 
was performed to identify relevant biological pathways 
according to significant gene expression. To incorporate 
information from previous research on the identified 
miRNAs, the target networks of the relevant biological 
pathways, especially those related to cancer development, 
were predicted using commercially available software 
(Ingenuity Systems, Redwood City CA).
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Quantitative real-time Pcr
Quantitative Real-Time PCR (qRT-PCR) was 
performed using the TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems, Foster City 
CA, USA) on an Agilent Technologies Stratagent 
Mx3000P (USA). A 500 ng mass of total RNA in 1 μL 
of RNase-free water was used in 20 μL of RT mix. The 
following primer pairs were used: has-miR-770-5p 
(ABI miRNA specific primers, ABI#002002), ERCC2 
sense: 5′-CATGGCATACCAGAGAGCATATCC-3′ and 
antisense: 5′-AGTTGAGCAACTTTCGAAGCTCTTC-3′ 
(GenePharma Co., Ld, ShangHai, China). The products 
were detected with SYBR Green I, and relative miRNA 
or mRNA levels were calculated using the comparative 
Ct (cycle threshold, 2-DDCt) method with U6 and GAPDH 
as the endogenous controls, respectively. Samples from 
at least three independent experiments, each measured in 
duplicate, were analyzed, and the data are expressed as 
the mean ± SD.
Mts cell viability assay 
Cell survival was determined using the CellTiter 
96® AQueous Non-Radioactive Cell Proliferation Assay 
kit (Cat#P9625; Promega Co., USA). Briefly, cells were 
cultured in 96-well plates at a density of 1 × 103/well for 
48 h after transfection, and then treated with 0, 5, 10, 15, 
20, 30, 40, 50, 60, 70, 85 or 100 μM cisplatin for 48 h. 
MTS/PMS solution composed of 20 μL each of a novel 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] and an electron coupling 
reagent (phenazine methosulfate; PMS) was added to one 
96-well plate for a total volume of 100 μL with cultured 
cells followed by incubation at 37°C in a humidified, 5% 
CO2 atmosphere for 1 h. The absorbance at 490 nm was 
measured using an ELISA plate reader (PowerWavex 340, 
Bio-Tek Instruments Inc., Winooski, VT, USA). Each 
point represents the mean ± S.D. of triplicates. Responses 
to drug treatment were assessed by standardizing treatment 
groups to untreated controls.
Cellular apoptosis assay with flow cytometry and 
tunEL 
Annexin V binding with propidium iodide (PI) 
staining was performed using the MuseTM Annexin V 
εt Dead Cell kit (Merck KGaA, Darmstadt, Germany). 
Ovarian cancer cells were seeded at 1 × 105 cells/mL 
in 6-well plates and incubated at 37°C in a humidified 
atmosphere with 5% CO2 for 48 h after transfection. C13 
cells were then treated with 30 μM, OV2008 cells with 
20 μM, and A2780CP and A2780S cells with 15 μM 
cisplatin for 48 hours, after which cells were dissociated 
using 0.05% EDTA-free trypsin and washed with cold 
PBS. Approximately 1 × 106 cells were suspended in 
100 μL of Annexin V incubation reagent. After incubation 
in the dark for 20 minutes at room temperature, cellular 
fluorescence was analyzed with a MuseTM Cell Analyzer 
(EMD Millipore Co., Germany) within 30 minutes. 
Control tubes containing binding buffer only and 
cells treated with Annexin V alone or PI alone were 
initially used to calibrate the instrument. The nuclear 
morphology of apoptotic cells was determined at the 
same time using the Showed TUNEL in situ apoptosis 
detection kit (KeyGene Biotech Inc., China) following 
the manufacturer’s instructions. Apoptotic cells (brown 
staining) were counted under a microscope. 
mirnA and rnA in situ hybridization (IsH)
All reagents were maintained in an RNase-free 
environment to minimize RNase contamination. ISH 
was performed on patient FFPE sections according to 
previously described protocols [33]. The probes used for 
ISH were hsa-miR-770-5p (Exiqon; Cat#38422-01) and 
human ERCC2 (an EcoRI-BamH1 fragment with antisense 
and sense digoxigenin-labeled riboprobes which were 
in vitro-transcribed from the full-length human ERCC2 
coding sequence according to the Boehringer-Mannheim-
Roche protocol). After removing the liquid mounting 
medium (LMM, Cat#19477; Aqueous Mounting Media, 
Quick-Mount 480l Daido Sangyo Co. LDT, Tokyo Japan), 
the transferred sections were treated with proteinase K (30 
μg/mL, Amresco; Cat No: 1227B016) for 5 min, followed 
by three washes in PBS. The sections were incubated with 
pre-hybridization buffer (10 mL formamide, 5 mL 20× 
SSC, 2 mL 50× Denhardt’s, 250 μL 20 mg/mL yeast RNA, 
1000 μL 10 mg/mL salmon sperm DNA, 0.4 g blocking 
powder, and 1.75 mL DEPC-treated water) at 55°C for 
1 h. Hybridization buffer containing the probes for has-
miR-770-5p or ERCC2 was applied to each section and 
hybridized overnight at 55°C. On the second day, after 
washing with 2× SCC, the sections were incubated with 
anti-DIG-Fab-AP (Roche; Cat#11376621) for 2 h at room 
temperature. After washing, the sections were stained with 
BCIP (3.5 μL/mL)/NBT (4.5 μL/mL) solution (Amresco; 
Cat# 0885/0329) in a humidified chamber at room 
temperature in the dark overnight. Then, the sections were 
counterstained with nuclear fast red. After dehydration 
in ascending concentrations of ethanol and clearing in 
xylene, the sections were mounted in mounting medium. 
Positive controls and no-probe controls were included for 
each hybridization procedure.
reverse transcription Pcr
Total RNA was prepared using Trizol reagent 
following manufacturer’s instructions. Reverse 
transcription-polymerase chain reaction (RT-PCR) was 
conducted as previously described [34, 35]. Newly 
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synthesized cDNA was amplified by PCR. The 20 μL 
reaction mixture contained 10 μL of cDNA template, 
5 × 5 μL PCR Buffer, 0.25 μL of Taq polymerase, 
and 0.5 μL of primer mixtures. The following 
primers were used: for ERCC2 expression, sense: 
5′-CATGGCATACCAGAGAGCATATCC-3′ and antisense: 
5′- AGTTGAGCAACTTTCGAAGCTCTTC-3′ (product 
size, 110 bp); for GAPDH (housekeeping gene) expression, 
sense: 5′-CATGAGAAGTATGACAACAGCCT-3′ and 
antisense: 5′-AGTCCTTCCACGATACCAAAGT-3′ 
(product size, 113 bp). The RT-PCR cycle was as follows: 
RT at 42°C for 45 min, 85°C for 5 min; PCR at 94°C 
for 30 s, 60°C for 30 s, and 72°C for 1 min, followed by 
40 cycles of amplification. PCR products were analyzed 
with 1.5% agarose gel electrophoresis in the presence 
of ethidium bromide for UV light transilluminator 
visualization.
Western blot analysis
Harvested cells were lysed in lysis buffer (Beyotime 
Institute of Biotechnology, Shanghai, CN), and lysates 
were evaluated for protein concentration using the BCA 
method (Beyotime Institute of Biotechnology, Shanghai, 
CN). Proteins (20 μg) were separated on 10% SDS-
PAGE gels and transferred to nitrocellulose membranes. 
Membranes were blocked in PBS containing 0.05% Tween 
20 (TBST)-5% nonfat milk and incubated with primary 
antibody (rabbit anti-ERCC2, 1:500 and rabbit anti-β-
actin, 1:1000; ProteinTech) in PBST-5% nonfat milk 
overnight at 4°C. After secondary antibody incubation, 
membranes were visualized with BeyoECL Plus A/B 
detection kit (Beyotime Institute of Biotechnology, 
Shanghai, CN).
comet assay 
The Single Cell Gel Electrophoresis assay (also 
known as Comet Assay) is a sensitive technique for 
measuring DNA strand breaks in individual cells. This is a 
standard technique for evaluation of DNA biomonitoring, 
genotoxicity, and damage/repair [27, 36]. The assay was 
performed as described by Carlos et al. [34] using the 
DNA Damage Detection Kit (KeyGEN BioTECH, Inc, 
Nanjing, China) with some modifications. Cells were 
exposed to cisplatin for 1 h, washed, and incubated at 37°C 
with 5% CO2 for 48 hours. Next, the cells were trypsinized 
and resuspended in 1 mL culture medium. After that, 
10 μL of cells (1 × 104) were encapsulated in 75 μL 0.7% 
low-melting-point agarose at 37ºC. This mixture was 
layered onto slides precoated with 0.5% standard agarose 
and covered with a coverslip. The agarose was allowed 
to solidify for 10 min at 4ºC, and then the coverslip was 
gently removed. Then, the slides were immersed in a 
precooled lysis buffer (Cat# KGA240) for at least 90 min 
at 4ºC followed by incubation in an alkaline buffer (1 mM 
EDTA and 300 mM NaOH; pH >13) for 60 minutes at 
room temperature to allow for DNA unwinding and alkali-
labile site expression. Electrophoresis was conducted in 
the same alkaline buffer for 30 minutes at 25V (0.86 
V/cm) and 300 mA. After electrophoresis, the slides 
were washed at least three times with 0.4 mM Tris-HCl 
(pH = 7.5) prior to staining with propidium iodide (PI) 
(20 μL) (KeyGEN BioTECH, Inc, Nanjing, China) for 
10 min. Comet tails were visualized using a fluorescence 
microscope with a FITC filter. In these experiments, cells 
with high amounts of cisplatin-induced cross-links have 
shorter tails compared to cells in which cross-links have 
been repaired effectively. This is because unrepaired 
platinum-induced DNA cross-links remain together after 
DNA degradation, resulting in larger DNA fragments 
[37, 38]. The tail length is proportional to the DNA repair. 
DNA was stained and the percentage of DNA in comet 
tails, tail length (in μm), tail moment (TM), and tail olives 
moment (TOM) were quantified to determine the extent of 
DNA damage/repair (CASP 1.2.3beta2 version, Krzysztof 
Konca, CaspLab.com). 
statistical analysis 
SPSS 17.0 (Chicago, IL, USA) was used for all 
quantitative analyses, except for microarray data. Data 
are expressed as arithmetic mean ± SD of the number 
(n) of experiments. Samples were analyzed with 
repeated measures analysis of variance, and differences 
in incidences were analyzed using one-way ANOVA. 
Differences in positive area and integrated optical density 
(IOD) in each field of the ×400 in situ hybridization 
photographs were determined using Image-Pro plus vision 
6.0. Overall survival was defined as the time from initial 
cytoreductive surgery to the date of the last follow-up or 
death. Survival time courses were evaluated using the 
Kaplan-Meier method, and groups were compared using 
the log rank test. p < 0.05 was considered statistically 
significant.
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